自身免疫性疾病的异基因干细胞移植：非清髓性预处理方案

Allogeneic stem cell transplantation for autoimmune diseases: nonmyeloablative conditioning regimens.

作者信息

Oyama Y, Traynor A E, Barr W, Burt R K

机构信息

Division of Immunotherapy, Northwestern University Medical School, 320 E. Superior, 3-489, Chicago, IL 60611, USA.

出版信息

Bone Marrow Transplant. 2003 Aug;32 Suppl 1:S81-3. doi: 10.1038/sj.bmt.1703950.

DOI:10.1038/sj.bmt.1703950

PMID:12931250

Abstract

Hematopoietic stem cell transplantation (HSCT) for autoimmune diseases have been, because of safety reasons, overwhelmingly autologous. Results are, in general, encouraging with improvement in quality of life, a remission of up to several years, and perhaps in some diseases improved survival. This indicates that further study of autologous HSCT especially under phase III design is warranted. However, the ultimate goal of HSCT is cure of otherwise incurable autoimmune diseases. For this reason, allogeneic HSCT in carefully selected high-risk patients with autoimmune diseases using strategies to minimize both regimen-related toxicity and graft-versus-host disease (GVHD) is ongoing at Northwestern University and will be reviewed briefly.

摘要

出于安全考虑，用于治疗自身免疫性疾病的造血干细胞移植（HSCT）绝大多数都是自体移植。总体而言，结果令人鼓舞，患者生活质量得到改善，缓解期长达数年，在某些疾病中或许还能提高生存率。这表明有必要对自体HSCT进行进一步研究，尤其是开展III期研究。然而，HSCT的最终目标是治愈原本无法治愈的自身免疫性疾病。因此，西北大学正在对精心挑选的患有自身免疫性疾病的高危患者进行异基因HSCT，采用策略将与治疗方案相关的毒性和移植物抗宿主病（GVHD）降至最低，并将对此进行简要回顾。